Results 271 to 280 of about 1,150,712 (337)

Reversing the "cold" tumor microenvironment: the role of neoantigen vaccines in prostate cancer. [PDF]

J Transl Med
Wang J, Guo R, Zhang L, Zuo W, Li X, Zhang S, Tan Q, Ma J.   +7 more
europepmc   +1 more source

Maximizing Efficacy of Cancer Nanovaccines and Immune Cells Landscape in Responders and Non‐Responders to Immunotherapy

Advanced Science, EarlyView.
To maximize the efficacy of cancer vaccines, adjuvants, collection, lysis, purification, oxidation, loading sites, and sizes, etc., are investigated. The optimized cancer nanovaccines loading whole tumor antigens can cure all or most tumor‐bearing mice in multiple mouse cancer models.
Xiangxiang Xu, Lu Diao, Jin Wang, Ao Zhu, Xianlan Chen, Yan Zheng, Yuhan Liu, Kang Hu, Jiashan Zhu, Cheng Ding, Chang Li, Yunzhi Pan, Jun Zhao, Mi Liu   +13 more
wiley   +1 more source

Evaluating an AI Chatbot "Prostate Cancer Info" for Providing Quality Prostate Cancer Screening Information: Cross-Sectional Study.

JMIR Cancer
Owens OL, Leonard MS.
europepmc   +1 more source

Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. [PDF]

Clin Proteomics
Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli M.   +20 more
europepmc   +1 more source

Allelic loss of chromosomes 16q and 10q in human prostate cancer.

, 1990
B S Carter, Charles M. Ewing, W. Steven Ward, Brent F.G. Treiger, Tilly Aalders, Jack A. Schalken, Jonathan I. Epstein, William B. Isaacs   +7 more
openalex   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

Advanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan, Kun Shao, Roopa Hebbandi Nanjundappa, Daniel‐Jiajun Yu, Marianne Stanford, Huile Gao, Channakeshava Sokke Umeshappa   +6 more
wiley   +1 more source

Role of Tumor Microenvironment in Prostate Cancer Immunometabolism. [PDF]

Biomolecules
Wang Y, Chen Y, Wang J.
europepmc   +1 more source

Targeting Intratumoral Copper Inhibits Tumor Progression via p62‐Mediated EZH2 Degradation and Potentiates Anti‐PD‐1 Immunotherapy in Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
The authors find that by targeting intratumoral copper, they can enhance p62‐mediated ubiquitination of EZH2 at the Ub‐K63 site by suppressing copper binding to SMURF2, an E3 ligase of EZH2, leading to its autophagic degradation. This mechanism suppressed OSCC progression and potentiated anti‐PD‐1 immunotherapy, highlighting a potential new therapeutic
Xiaohu Lin, Wanling Chen, Bo Li, Zhang Zhao, Zhonglin Yu, Xu‐Yun Zhao, Xuan Zhou, Zhien Feng, Chengzhong Lin, Wei Cao   +9 more
wiley   +1 more source

Talazoparib for prostate cancer and breast cancer. [PDF]

Aust Prescr
europepmc   +1 more source

Evaluation of [18F]PSMA-1007 uptake variability in patients with prostate cancer. [PDF]

Clin Physiol Funct Imaging
Trägårdh E, Larsson M, Minarik D, Enqvist O, Edenbrandt L.   +4 more
europepmc   +1 more source